1-13 of 13
Clemens Krepler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Gao Zhang, Lawrence W. Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Sadek, Aurelie Beroard, Min Xiao, Tian Tian, Jiufeng Tan, Umar Saeed, Eric Sugarman, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Sengottuvelan Murugan, Rajasekharan Somasundaram, Bradley Garman, Bradley Wubbenhorst, Jonathan Woo, Xiangfan Yin, Qin Liu, Dennie T. Frederick, Benchun Miao, Wei Xu, Giorgos C. Karakousis, Xiaowei Xu, Lynn M. Schuchter, Tara C. Mitchell, Lawrence N. Kwong, Ravi K. Amaravadi, Yiling Lu, Genevieve M. Boland, Zhi Wei, Katherine Nathanson, Utz Herbig, Gordon B. Mills, Keith T. Flaherty, Meenhard Herlyn, Jerry W. Shay
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4771–4784.
https://doi.org/10.1158/1078-0432.CCR-17-2773
Published: 01 October 2018
View article titled, Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Open the PDF for Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma in another window
Includes: Multimedia, Supplementary data
Journal Articles

Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers

Heinz Hammerlindl, Dinoop Ravindran Menon, Sabrina Hammerlindl, Abdullah Al Emran, Joachim Torrano, Katrin Sproesser, Divya Thakkar, Min Xiao, Victoria G. Atkinson, Brian Gabrielli, Nikolas K. Haass, Meenhard Herlyn, Clemens Krepler, Helmut Schaider
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 1090–1102.
https://doi.org/10.1158/1078-0432.CCR-16-2118
Published: 28 February 2018
View article titled, Acetylsalicylic Acid Governs the Effect of Sorafenib in <em>RAS</em>-Mutant Cancers
Open the PDF for Acetylsalicylic Acid Governs the Effect of Sorafenib in <em>RAS</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models

Hyoung Kim, Erin George, Ryan L. Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark A. Morgan, Meenhard Herlyn, Eric J. Brown, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3097–3108.
https://doi.org/10.1158/1078-0432.CCR-16-2273
Published: 14 June 2017
View article titled, Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <em>BRCA</em>-Mutant Ovarian Cancer Models
Open the PDF for Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <em>BRCA</em>-Mutant Ovarian Cancer Models in another window
Includes: Supplementary data
Journal Articles

Abstract PR02: Humanized mouse melanoma model using patient-derived xenografts

Clemens Krepler, Michela Perego, Mizuho Kalabis, Marilda Beqiri, Denitsa Hristova, Min Xiao, Nicholas J. Petrelli, Rajasekharan Somasundaram, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): PR02.
https://doi.org/10.1158/1557-3265.PDX16-PR02
Published: 15 August 2016
View article titled, Abstract PR02: Humanized mouse melanoma model using patient-derived xenografts
Journal Articles

Abstract A02: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers

Erin George, Hyoung Kim, Janos Tanyi, Ryan Ragland, Eric Brown, Rugang Zhang, Patricia Brafford, Katrin Sproesser, Marilda Beqiri, Adina Vultur, Clemens Krepler, Brandon Weis, Kate Nathanson, Yuling Lu, Gordon Mills, Mehran Makvandi, Robert Mach, Mark Morgan, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A02.
https://doi.org/10.1158/1557-3265.PDX16-A02
Published: 15 August 2016
View article titled, Abstract A02: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers
Journal Articles

Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization

Clemens Krepler, Katrin Sproesser, Marilda Beqiri, Min Xiao, Patricia Brafford, Wei Xu, Bradley Garman, Jennifer Wargo, Michael A. Davies, Dennie T. Frederick, Keith T. Flaherty, David Hoon, Joseph J. Bennett, Michael Guarino, Nicholas J. Petrelli, David Elder, Xiaowei Xu, Giorgos Karakousis, KATHERINE L. NATHANSON, Lynn Schuchter, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A01.
https://doi.org/10.1158/1557-3265.PDX16-A01
Published: 15 August 2016
View article titled, Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization
Journal Articles

Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia A. Brafford, Batool Shannan, Marilda Beqiri, Qin Liu, Wei Xu, Bradley Garman, Katherine L. Nathanson, Xiaowei Xu, Giorgos C. Karakousis, Gordon B. Mills, Yiling Lu, Tamer A. Ahmed, Poulikos I. Poulikakos, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn M. Schuchter, Ashani T. Weeraratna, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1592–1602.
https://doi.org/10.1158/1078-0432.CCR-15-1762
Published: 31 March 2016
View article titled, Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Open the PDF for Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies in another window
Includes: Supplementary data
Journal Articles

Abstract A08: Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patient-derived xenograft (PDX) model.

Hyoung Kim, Erin George, Eric Brown, Rugang Zhang, Clemens Krepler, Janos Tanyi, Rachel Lee, Mark Morgan, Meenhard Herlyn, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): A08.
https://doi.org/10.1158/1557-3265.OVCA15-A08
Published: 15 January 2016
View article titled, Abstract A08: Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patient-derived xenograft (PDX) model.
Journal Articles

Abstract B46: Use of a novel orthotopic ovarian cancer transplant patient derived xenograft model as a preclinical platform for bench to bedside research.

Erin George, Hyoung Kim, Clemens Krepler, Janos Tanyi, Zhi Wei, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Adina-Monica Vultur, Rachel Lee, Mark Morgan, Ronny Drapkin, Tan Ince, Meenhard Herlyn, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): B46.
https://doi.org/10.1158/1557-3265.OVCA15-B46
Published: 15 January 2016
View article titled, Abstract B46: Use of a novel orthotopic ovarian cancer transplant patient derived xenograft model as a preclinical platform for bench to bedside research.
Journal Articles

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Tao Wang, Min Xiao, Yingbin Ge, Clemens Krepler, Eric Belser, Alfonso Lopez-Coral, Xiaowei Xu, Gao Zhang, Rikka Azuma, Qin Liu, Rui Liu, Ling Li, Ravi K. Amaravadi, Wei Xu, Giorgos Karakousis, Tara C. Gangadhar, Lynn M. Schuchter, Melissa Lieu, Sanika Khare, Molly B. Halloran, Meenhard Herlyn, Russel E. Kaufman
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1652–1664.
https://doi.org/10.1158/1078-0432.CCR-14-1554
Published: 31 March 2015
View article titled, BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Open the PDF for BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth in another window
Includes: Supplementary data
Journal Articles

The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells

Clemens Krepler, Srinivas K. Chunduru, Molly B. Halloran, Xu He, Min Xiao, Adina Vultur, Jessie Villanueva, Yasuhiro Mitsuuchi, Eric M. Neiman, Christopher Benetatos, Katherine L. Nathanson, Ravi K. Amaravadi, Hubert Pehamberger, Mark McKinlay, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1784–1794.
https://doi.org/10.1158/1078-0432.CCR-12-2518
Published: 02 April 2013
View article titled, The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Open the PDF for The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells in another window
Includes: Supplementary data
Journal Articles

Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas

Clemens Krepler, Meenhard Herlyn, Jessie Villanueva, Ahmed Samatar, Yuhao Chen, Molly Halloran, Minu Samanta, Xu He, Adina Vultur, Bradley Wubbenhorst, Katherine Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B12.
https://doi.org/10.1158/1078-0432.MECHRES-B12
Published: 04 March 2013
View article titled, Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas
Open the PDF for Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas in another window
Journal Articles

Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine

Stefan Wagner, Clemens Krepler, Dorothee Allwardt, Julia Latzka, Sabine Strommer, Otto Scheiner, Hubert Pehamberger, Ursula Wiedermann, Christine Hafner, Heimo Breiteneder
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8178–8183.
https://doi.org/10.1158/1078-0432.CCR-08-0371
Published: 15 December 2008
View article titled, Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine
Open the PDF for Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine in another window